Flubrotizolam

Summary

Flubrotizolam, known chemically as 2-bromo-4-(2-fluorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine, is a thienotriazolodiazepine analog. It possesses significant sedative and anxiolytic properties, and it has been marketed and distributed as a substance falling under the category of designer drugs.

Identifiers
IUPAC name
CAS Number57801-95-3 
PubChem CID3044878
UNIIZWK85P59MH
CompTox Dashboard (EPA)DTXSID80206503
Chemical and physical data
FormulaC15H10BrFN4S
Molar mass377.24 g·mol−1

FAQ

  • What is Flubrotizolam?
  • Flubrotizolam is a chemical compound belonging to the thienotriazolodiazepine class. It is known for its sedative and anxiolytic effects and has been marketed as a designer drug.
  • Is Flubrotizolam legal?
  • The legal status of Flubrotizolam varies by country and region. It’s essential to check the specific laws and regulations in your area, as designer drugs like Flubrotizolam may be subject to legal restrictions.
  • What are the effects of Flubrotizolam?
  • Flubrotizolam primarily produces sedative and anxiolytic effects. It may induce relaxation, reduce anxiety, and promote sleep. However, it can also have side effects and potential risks, mainly when abused or misused.
  • Is Flubrotizolam safe to use?
  • The safety of using Flubrotizolam is a subject of concern. As a designer drug, it has yet to undergo the rigorous testing and quality control that pharmaceutical medications typically undergo. This lack of regulation can make its safety unpredictable.
  • What are the potential risks of using Flubrotizolam?
  • Using Flubrotizolam may carry several risks, including addiction, dependency, withdrawal symptoms, and adverse health effects. The drug’s long-term effects and safety profile are not well-documented.
  • Is Flubrotizolam addictive?
  • Like many drugs with sedative properties, Flubrotizolam has the potential to be addictive. Repeated use can lead to physical and psychological dependence, making it challenging to quit.
  • What are the withdrawal symptoms associated with Flubrotizolam?
  • Withdrawal symptoms from Flubrotizolam can be severe and include anxiety, insomnia, restlessness, and rebound symptoms similar to the condition it was taken to treat (e.g., anxiety).
  • Can Flubrotizolam be used as a medication?
  • Flubrotizolam is not approved for medical use in most countries, as it’s primarily marketed as a designer drug. Please do not attempt to self-medicate with it without the guidance of a healthcare professional.
  • What is the legal status of Flubrotizolam in my area?
  • The legal status of Flubrotizolam can vary widely by country, state, or region. Please consult your local drug enforcement agencies or government websites to find the most up-to-date information on its legal status.
  • Where can I find help if I have concerns about Flubrotizolam use?
  • If you or someone you know is struggling with Flubrotizolam use or addiction, it’s essential to seek help from a healthcare professional, counsellor, or a substance abuse treatment facility. They can provide guidance and support for managing substance abuse and addiction.

References

  1. US 4094984 – Synthesis of Novel 1,4-Diazepines: This patent, issued on June 13, 1978, pertains to the synthesis of 6-phenyl-8-bromo-4H-s-triazolo-[3,4C]-thieno-[2,3E]-1,4-diazepines and their salts. The patent is attributed to Boehringer Ingelheim, a pharmaceutical company known for its contributions to medicinal chemistry.
  2. Psychonauts and Benzodiazepines: A study conducted in July 2021, authored by Catalani, Botha, Corkery, Guirguis, Vento, Scherbaum, and Schifano, explores the quantitative structure-activity relationship (QSAR) of benzodiazepines often associated with recreational drug use. This research delves into the molecular mechanisms of these substances.
  3. In Silico Studies on Recreational Drugs: In a more recent study published in January 2023, Catalani, Floresta, Botha, Corkery, Guirguis, and Vento investigate the 3D quantitative structure-activity relationship (QSAR) predictions of both classified and newly designed designer benzodiazepines. The research offers insights into the potential effects and risks associated with these substances, using advanced computational modeling techniques.

Leave a Comment

Your email address will not be published. Required fields are marked *